168 related articles for article (PubMed ID: 19794412)
1. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
Zhou K; Donnelly L; Burch L; Tavendale R; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Lang CC; Palmer CN; Pearson ER
Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
3. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.
Pearson ER; Donnelly LA; Kimber C; Whitley A; Doney AS; McCarthy MI; Hattersley AT; Morris AD; Palmer CN
Diabetes; 2007 Aug; 56(8):2178-82. PubMed ID: 17519421
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
Swen JJ; Wessels JA; Krabben A; Assendelft WJ; Guchelaar HJ
Pharmacogenomics; 2010 Nov; 11(11):1517-23. PubMed ID: 21121772
[TBL] [Abstract][Full Text] [Related]
5. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
6. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH
Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303
[TBL] [Abstract][Full Text] [Related]
7. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
8. Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Schalekamp T; van Geest-Daalderop JH; de Vries-Goldschmeding H; Conemans J; Bernsen Mj Mj; de Boer A
Clin Pharmacol Ther; 2004 May; 75(5):394-402. PubMed ID: 15116052
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
11. Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing.
Grant RW; Wexler DJ
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):339-43. PubMed ID: 20222813
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
13. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
[TBL] [Abstract][Full Text] [Related]
14. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
15. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.
Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979
[TBL] [Abstract][Full Text] [Related]
16. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study.
Tranah GJ; Chan AT; Giovannucci E; Ma J; Fuchs C; Hunter DJ
Mol Carcinog; 2005 Sep; 44(1):21-30. PubMed ID: 15924351
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
18. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.
Guo Y; Zhang Y; Wang Y; Chen X; Si D; Zhong D; Fawcett JP; Zhou H
Drug Metab Dispos; 2005 Jun; 33(6):749-53. PubMed ID: 15764711
[TBL] [Abstract][Full Text] [Related]
19. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.
Holstein A; Hahn M; Patzer O; Seeringer A; Kovacs P; Stingl J
Eur J Clin Pharmacol; 2011 May; 67(5):471-6. PubMed ID: 21213107
[TBL] [Abstract][Full Text] [Related]
20. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
